Arecor Therapeutics plc
("Arecor" or the "Company")
Notice of Interim Results
Cambridge, UK, 24 September 2025: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, will announce its interim results for the six months ended 30 June on Thursday 25 September 2025.
Dr Sarah Howell, Chief Executive Officer, and David Ellam, Chief Financial Officer, will host a webcast for analysts and institutional investors at 3pm UK time on Thursday 25 September 2025. To register, please contact arecor@vigoconsulting.com. A copy of the interim results presentation will be released after the meeting on the Company website at www.arecor.com.
-ENDS-
For more information, please contact:
|
Arecor Therapeutics plc |
+44 (0) 1223 426060 |
|
Singer Capital Markets Advisory LLP (NOMAD and Broker) |
+44 (0) 20 7496 3000 |
|
Phil Davies, Sam Butcher |
|
|
Vigo Consulting |
+44 (0) 20 7390 0230 |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a clinical stage biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases. The Company is applying its proprietary technology platform, Arestat™, to develop a portfolio of proprietary products, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. Its lead product is AT278, the only ultra-concentrated (500U/mL) ultra-rapid acting insulin which is being co-developed with a US Automated Insulin Delivery pump device partner. Arecor is also developing a novel oral delivery platform for peptides (e.g. GLP-1 receptor agonists) targeting the obesity and diabetes markets. The Company is listed on AIM (AIM: AREC) and is based in Cambridge, UK. For further details please see www.arecor.com